~（18）F-FDG PET/CT对治疗前淋巴瘤分期的临床价值

目的探讨18F-FDG PET/CT显像对治疗前淋巴瘤临床分期的价值。方法回顾性分析63例初次诊断为淋巴瘤病人的PET/CT及常规影像学检查结果。结果 PET/CT与常规影像学检查对63例淋巴瘤病人分期的一致率为30.2%（19/63）。与常规影像学检查结果相比,18F-FDG PET/CT显像使69.8%（44/63）的淋巴瘤病人临床分期发生改变。其中17.4%（11/63）的病例在PET/CT检查中发现有多区域淋巴结及多个结外器官受累,肝或骨髓受累,淋巴瘤的临床分期从Ⅰ期上调至Ⅳ期;有25.4%（16/63）的病例在PET/CT检查中发现多区域淋巴结累及,分期上调一期;其余27.0%（17/63）的病例在PET/CT检查中发现多区域淋巴结或多个结外器官受累,临床分期上调两期。结论 18F-FDG PET/CT显像对治疗前淋巴瘤临床分期的价值优于常规影像学检查,有利于制定合理有效的治疗方案。

THE CLINICAL VALUE OF 18F-FDG PET/CT FOR PRE-TREATMENT STAGING OF LYMPHOMA

Objective To evaluate the value of is F-FDG PET/CT imaging in pretherapy clinical staging of lymphoma. Methods A retrospective review was done in 63 patients with lymphoma diagnosed at first visit, their PET/CT and routine imaging results were analyzed. Results The concordance rate of 18FFDG PET/CT with routine imaging examination was 30.2% （19/63） in staging of 63 patients with lymphoma. Compared with routine imaging examination, 69.8% （44/63） of the patients with image of 18F-FDG PET/CT showed changes of clinical stage. Of whom, 17.4% （11/63） on PET/CT showed multi-regional lymphnode or organs-liver or bone marrow-were involved, the stage of the lymphoma was raised from stage 1 to stage 4, and 25.4% of the patients were found to have multi-regional lymphnodes involved, the stage was up-regulated one phase; and 27.0% of patients with the grade to be raised by two stages because of lymphnode involvement in multiple regions and organs outside the lymphnodes. Conclusion 18F-FDG PET/CT is superior to routine imaging examination in pretherapy clinical staging of lympho- ma, which is helpful in making a reasonable and effective therapeutic schedule.